BMY
February 2, 2024 - AI Summary
Undervalued by 17.4% based on the discounted cash flow analysis.
Market cap | $99.17 Billion |
---|---|
Enterprise Value | $126.66 Billion |
Dividend Yield | $2.3015 (4.7%) |
Earnings per Share | $3.86 |
Beta | 0.0 |
Outstanding Shares | 2,026,758,715 |
Avg 30 Day Volume | 11,248,564 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 12.36 |
---|---|
PEG | -96.1 |
Price to Sales | 2.23 |
Price to Book Ratio | 3.5 |
Enterprise Value to Revenue | 2.81 |
Enterprise Value to EBIT | 15.46 |
Enterprise Value to Net Income | 15 |
Total Debt to Enterprise | 0.31 |
Debt to Equity | 1.35 |
No data
No data
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.